Treatment and complications of uveitis
Non-infectious uveitis is treated on a ladder: steroid delivered as locally as possible, then systemic steroid, then drugs that allow the steroid to be reduced, then a biologic. This lesson explains each rung, the NICE rules for adalimumab and the dexamethasone implant, and the complications that cause most of the visual loss: cataract, glaucoma, cystoid macular oedema, band keratopathy and hypotony.
Principles before any prescription
Three questions come before treatment. The first is whether the uveitis is infectious, because infection is treated with an antimicrobial and steroid alone makes it worse. The second is where the inflammation is, because that decides how the drug must be delivered. The third is whether sight is threatened, because the stronger treatments carry real risks and are justified only by a real threat.
The aim is not simply to settle one attack. It is to keep the eye free of inflammation for long enough to prevent the structural damage described at the end of this lesson, using the smallest total dose of steroid. Steroids work fast and reliably, which is why every rung of the ladder starts with them, but both the eye and the body pay for long courses. The other drugs exist to make long-term steroid unnecessary.
- Topical steroid with a cycloplegic, for anterior uveitis.
- Periocular or intravitreal steroid, for disease behind the lens in one eye, or for macular oedema.
- Systemic steroid, for sight-threatening or bilateral posterior disease.
- A steroid-sparing immunosuppressant: an antimetabolite or a calcineurin inhibitor.
- A biologic: adalimumab.
Local steroid: drops, injections and implants
Topical steroid drops, such as prednisolone acetate 1% and dexamethasone 0.1%, reach useful concentrations in the anterior chamber but not behind the lens. They are therefore the treatment for anterior uveitis and of little use on their own for intermediate or posterior disease. They are started frequently and tapered slowly. A cycloplegic such as cyclopentolate or atropine is given with them to relieve ciliary spasm and prevent posterior synechiae, as described in the lesson on anterior uveitis.
A periocular injection places a depot of long-acting steroid, usually triamcinolone 40 mg, beside the globe: either beneath Tenon's capsule or through the lower lid on to the orbital floor. The drug diffuses across the sclera over weeks. It suits disease in one eye, macular oedema, and patients in whom systemic steroid is best avoided.
An intravitreal steroid is injected through the pars plana directly into the vitreous cavity, where it achieves the highest concentration at the retina. The dexamethasone implant (Ozurdex) is a 0.7 mg biodegradable rod that releases drug for up to about six months. NICE technology appraisal TA460 recommends it for non-infectious uveitis in the posterior segment in adults only if there is active disease and worsening vision with a risk of blindness. A fluocinolone acetonide implant releases a low dose for up to three years and is recommended by NICE (TA590) for preventing relapse in recurrent non-infectious uveitis affecting the posterior segment.
Every form of steroid given to the eye has the same two ocular side effects: cataract, typically posterior subcapsular, and raised intraocular pressure. The closer the depot is to the eye and the longer it lasts, the greater the risk, so implants require regular pressure checks. An intravitreal injection also carries a small risk of introducing infection. The BNF lists active ocular infection and uncontrolled advanced glaucoma among the contraindications to the dexamethasone implant.
Systemic steroid
Oral prednisolone is used when posterior uveitis threatens sight, when both eyes are involved, or when local treatment has failed. It is started at a high dose, of the order of 1 mg per kilogram per day, and tapered over weeks to months as the eye settles. For disease that is about to destroy the macula or optic nerve, such as Vogt-Koyanagi-Harada disease or a severe attack of Behçet disease, treatment may begin with intravenous methylprednisolone, typically 1 g a day for three days. Reducing too quickly or stopping abruptly brings the inflammation back, and after a long course the adrenal glands are suppressed.
The systemic adverse effects are the ones known from general medicine: weight gain and Cushingoid appearance, raised blood glucose, hypertension, osteoporosis and fractures, peptic ulceration, mood and sleep disturbance, susceptibility to infection, and slowed growth in children. Bone protection is considered for anyone on a long course.
The working rule is that steroid is for getting control, not for keeping it. If the eye cannot be kept quiet on a low maintenance dose, commonly taken as prednisolone 7.5 mg a day or less, after about three months, a second drug is added so that the steroid can come down.
Steroid-sparing immunosuppressants
These drugs suppress the lymphocytes that drive uveitis. They take several weeks to work, so they are started under cover of steroid, which is then tapered. They are prescribed by specialists, often jointly with a rheumatologist, and all need regular blood monitoring. Indications are sight-threatening posterior disease, dependence on steroid, intolerance of steroid, and diseases known to do badly on steroid alone, such as Behçet disease, birdshot chorioretinopathy and sympathetic ophthalmia.
| Drug | Class and action | Points to know |
|---|---|---|
| Methotrexate | Antimetabolite. Inhibits dihydrofolate reductase, which is needed to make purines and pyrimidines. | Taken once a week, never daily. Folic acid reduces side effects. Bone marrow suppression and liver toxicity: full blood count, renal and liver function are monitored. Teratogenic. First choice in children with JIA uveitis. |
| Mycophenolate mofetil | Antimetabolite. Reduces lymphocyte proliferation. | Gastrointestinal upset and bone marrow suppression. Teratogenic: the MHRA requires pregnancy to be excluded and effective contraception used. |
| Azathioprine | Antimetabolite. Converted to mercaptopurine, a purine analogue. | Thiopurine methyltransferase (TPMT) activity is measured before starting, because low activity leads to severe bone marrow suppression. Can cause pancreatitis. |
| Ciclosporin | Calcineurin inhibitor. Stops T cells producing lymphokines such as interleukin-2. | Nephrotoxicity and hypertension are the limiting effects, so blood pressure and creatinine are monitored. Also gum overgrowth, excess hair and tremor. |
| Tacrolimus | Calcineurin inhibitor. | Nephrotoxicity, neurotoxicity and diabetes. |
Methotrexate and mycophenolate are the usual first choices, and a randomised trial comparing them found similar rates of control. All of these drugs increase the risk of infection.
Adalimumab and the NICE criteria
Adalimumab is a human monoclonal antibody that binds tumour necrosis factor alpha (TNF), a cytokine central to intraocular inflammation. It is given by subcutaneous injection. The BNF dose for uveitis in adults is 80 mg at week 0, then 40 mg every two weeks starting at week 1.
NICE technology appraisal TA460 recommends adalimumab for non-infectious uveitis in the posterior segment in adults who have had an inadequate response to corticosteroids, only if all of the following apply:
- active disease, meaning current inflammation in the eye;
- inadequate response or intolerance to immunosuppressants;
- systemic disease, or both eyes affected, or one eye affected if the second eye has poor visual acuity;
- worsening vision with a high risk of blindness.
NICE also sets stopping rules. Adalimumab is stopped if there are new active inflammatory chorioretinal or retinal vascular lesions, a two-step increase in vitreous haze or anterior chamber cell grade, or a fall in best corrected visual acuity of three or more lines.
Before starting, patients are screened for tuberculosis and hepatitis B, because blocking TNF can reactivate both. The BNF contraindicates adalimumab in moderate or severe heart failure and in severe infection. It can also exacerbate demyelinating disease, which matters in uveitis because intermediate uveitis is associated with multiple sclerosis: the manufacturer advises assessing for demyelination before and during treatment. In children, adalimumab is used with methotrexate for JIA-associated uveitis that has not responded to methotrexate alone. Infliximab is another TNF inhibitor used by specialists, particularly in Behçet disease. Etanercept is not recommended for uveitis.
Complications
Most visual loss in uveitis comes from structural complications, and several are caused by the treatment as much as by the disease. NICE Clinical Knowledge Summaries names cystoid macular oedema, cataract and glaucoma as the major causes.
Cystoid macular oedema (CMO) is the most common cause of visual impairment in uveitis. Inflammatory mediators break down the blood-retinal barrier, and fluid collects in cyst-like spaces around the fovea. OCT shows the cysts, and fluorescein angiography shows dye pooling in a petal pattern. It can persist when the eye otherwise looks quiet. Treatment is better control of the inflammation, with periocular or intravitreal steroid aimed at the macula. Long-standing oedema damages the photoreceptors permanently.
Cataract results from chronic inflammation and from steroid by any route, and is usually posterior subcapsular. Surgery in a uveitic eye risks a severe flare and macular oedema, so it is done only after the eye has been free of inflammation for about three months, usually with extra steroid cover around the operation. Posterior synechiae and a small pupil make the surgery harder.
Raised pressure and glaucoma arise in several ways, and working out which applies decides the treatment.
| Mechanism | Angle | Explanation |
|---|---|---|
| Trabecular blockage | Open | Inflammatory cells and debris clog the meshwork |
| Trabeculitis | Open | The meshwork itself is inflamed, as in herpetic uveitis |
| Trabecular scarring | Open | Repeated attacks scar the outflow channels |
| Steroid response | Open | Steroid increases outflow resistance in susceptible people |
| Pupil block | Closed | Posterior synechiae around the whole pupil cause iris bombe |
| Peripheral anterior synechiae | Closed | The peripheral iris sticks to the angle |
| Neovascular | Closed | New vessels grow over the angle after retinal ischaemia |
Pressure is lowered with aqueous suppressants such as beta-blockers and carbonic anhydrase inhibitors. Pilocarpine is avoided, because a miotic increases breakdown of the blood-aqueous barrier and encourages synechiae. Laser trabeculoplasty is not used, as it provokes inflammation. Pupil block is relieved by an iridotomy. Eyes that fail medical treatment need drainage surgery.
Band keratopathy is a deposit of calcium hydroxyapatite in the superficial cornea, at the level of Bowman layer. It forms a grey-white horizontal band across the exposed part of the cornea between the lids, starting at the 3 and 9 o'clock positions, with a clear zone separating it from the limbus. It is a sign of long-standing inflammation and is characteristic of JIA-associated uveitis in children. It blurs vision and causes irritation. It is removed by scraping the epithelium and applying the chelating agent EDTA, which dissolves the calcium.
Hypotony means an abnormally low intraocular pressure. In chronic uveitis the ciliary body is damaged by inflammation, or pulled away by fibrous membranes, and stops making enough aqueous. The soft eye develops folds at the macula and loses vision. If the process continues the globe shrinks and becomes disorganised, an end stage called phthisis bulbi.
Summary
- Infection is excluded before immunosuppression, and the route of steroid is matched to the site of inflammation.
- Topical steroid treats anterior uveitis only; disease behind the lens needs periocular, intravitreal or systemic steroid.
- The dexamethasone intravitreal implant is recommended by NICE TA460 for active non-infectious posterior segment uveitis with worsening vision and a risk of blindness.
- All ocular steroid causes cataract and raised intraocular pressure.
- A steroid-sparing drug is added when control needs more than a low dose of prednisolone, around 7.5 mg a day, for longer than about three months.
- Methotrexate is given once weekly with folic acid; azathioprine needs a TPMT test; ciclosporin causes hypertension and nephrotoxicity; mycophenolate is teratogenic.
- NICE TA460 recommends adalimumab for active posterior segment uveitis after failure of steroid and immunosuppressants, with bilateral or systemic disease and worsening vision at high risk of blindness.
- Adalimumab requires screening for tuberculosis and hepatitis B and caution in demyelinating disease and heart failure.
- Cystoid macular oedema is the most common cause of visual impairment in uveitis.
- Pilocarpine is avoided in uveitic glaucoma; cataract surgery waits until the eye has been quiet for about three months.
Check yourself
Quick recall on this lesson. These are easier than the question bank.
Written for revision. It is not a source of clinical advice, and guidance changes.